Citigroup Inc Adagio Therapeutics, Inc. Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

A detailed history of Citigroup Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 60,523 shares of ADGI stock, worth $200,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,523
Previous 17,920 237.74%
Holding current value
$200,331
Previous $59,000 238.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
N/A
42,603 Added 237.74%
60,523 $200,000
Q2 2024

Aug 12, 2024
SELL
N/A
-183,812 Reduced 91.12%
17,920 $59,000
Q1 2024

May 10, 2024
SELL
N/A
-67,993 Reduced 25.21%
201,732 $667,000
Q4 2023

Feb 09, 2024
SELL
N/A
-239,440 Reduced 47.03%
269,725 $892,000
Q3 2023

Nov 09, 2023
SELL
N/A
-1,817,981 Reduced 78.12%
509,165 $1.69 Million
Q2 2023

Aug 10, 2023
BUY
N/A
2,325,904 Added 187270.84%
2,327,146 $7.7 Million
Q1 2023

May 11, 2023
SELL
N/A
-477 Reduced 27.75%
1,242 $4,000
Q4 2022

Feb 09, 2023
BUY
$3.08 - $4.05 $2,904 - $3,819
943 Added 121.52%
1,719 $5,000
Q3 2022

Nov 10, 2022
SELL
$2.97 - $4.83 $8,951 - $14,557
-3,014 Reduced 79.53%
776 $2,000
Q2 2022

Aug 10, 2022
SELL
$2.54 - $4.52 $54,645 - $97,243
-21,514 Reduced 85.02%
3,790 $12,000
Q1 2022

May 12, 2022
SELL
$3.81 - $10.77 $269,325 - $761,320
-70,689 Reduced 73.64%
25,304 $115,000
Q4 2021

Feb 10, 2022
BUY
$6.35 - $47.04 $593,705 - $4.4 Million
93,497 Added 3745.87%
95,993 $697,000
Q3 2021

Nov 10, 2021
BUY
$20.88 - $56.08 $52,116 - $139,975
2,496 New
2,496 $105,000

Others Institutions Holding ADGI

# of Institutions
78
Shares Held
63.9M
Call Options Held
2.3K
Put Options Held
2.1K
View Full List

About Adagio Therapeutics, Inc.

ADGI Quotes by TradingView
  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email